Results 161 to 170 of about 11,390 (207)

Morning vs Bedtime Dosing and Nocturnal Blood Pressure Reduction in Patients With Hypertension: The OMAN Randomized Clinical Trial.

JAMA Netw Open
Ye R, Yang X, Zhang X, Zuo X, Li Y, Jia S, Xu M, Liu L, Wang S, Liu K, Meng Q, Liao H, Zhang Z, Shi R, Li X, Liu X, Sun L, Zhang X, Ran Q, Chen F, Gao Q, Yao W, Shi H, Liu T, Ma K, Liu L, Chen K, Gao J, Chen X.   +28 more
europepmc   +1 more source

Palmoplantar-predominant bullous pemphigoid with acral purpuric lesions: An unusual presentation. [PDF]

JAAD Case Rep
Martínez Rozas L, Floristán Muruzábal MU, Pinedo-Moraleda FJ, Estebaranz JLL.   +3 more
europepmc   +1 more source

Letter to the Editor: Fimasartan-Induced Liver Injury and Update on Hepatotoxicity Risks. [PDF]

J Korean Med Sci
Lee J, Chin S, Kim SG, Kim YS, Yoo JJ.
europepmc   +1 more source

Editorial Note: Olmesartan Potentiates the Anti-Angiogenic Effect of Sorafenib in Mice Bearing Ehrlich's Ascites Carcinoma: Role of Angiotensin (1-7). [PDF]

PLoS One
PLOS ONE Editors.
europepmc   +1 more source

Pathognomonic Features of Olmesartan-Induced Collagenous Sprue Resulting in Severe Small Bowel Malabsorption. [PDF]

Cureus
Goshgarian MA, Laczek J, Lustberg M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Olmesartan

2017
Olmesartan is an angiotensin receptor blockers with actions similar to those of losartan; it is used for the treatment of high blood pressure by relaxing blood vessels for this reason blood can flow more easily. It could be used alone or in combination with other antihypertensive drugs.
Abdulrahman A, Al-Majed, Ahmed H H, Bakheit, Hatem A, Abdel Aziz, Abdulelah A M, Al-Jallal   +3 more
  +5 more sources

Olmesartan Medoxomil

Drugs, 2002
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20
Gregory T, Warner, Blair, Jarvis
openaire   +3 more sources

Olmesartan Medoxomil/Amlodipine

Drugs, 2009
black triangle Olmesartan medoxomil/amlodipine is a fixed-dose combination of olmesartan medoxomil and amlodipine, both established antihypertensive agents. Dose titration with the individual constituent drugs is recommended before switching to the equivalent fixed-dose combination.
Mark, Sanford, Susan J, Keam
openaire   +2 more sources